Company intelligence / Profile preview
Puyi Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Puyi Biotechnology’s lead products, including Corina Intrauterine Drug-Eluting System (approved 2024 in China) and BISORB Drug-Eluting Sinus Absorbable System (nationally registered in China, registered in Indonesia 2024), have both shown statistically significant and clinically meaningful efficacy in randomized, controlled trials, advancing new standards of care in intrauterine adhesion and chronic rhinosinusitis.
- Therapeutic areas
- Women's HealthPulmonology
- Modalities
- DeviceDrug-device combinationSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Puyi Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Puyi Biotechnology.